CeriBell (NASDAQ:CBLL) CFO Scott Blumberg Sells 846 Shares

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 846 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $25.00, for a total value of $21,150.00. Following the transaction, the chief financial officer owned 146,600 shares of the company’s stock, valued at $3,665,000. This trade represents a 0.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Scott Blumberg also recently made the following trade(s):

• On Wednesday, September 2nd, Scott Blumberg sold 652 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total transaction of $16,300.00.
• On Friday, August 21st, Scott Blumberg sold 1,521 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total transaction of $36,534.42.
• On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The shares were sold at an average price of $25.03, for a total value of $838,805.36.
• On Tuesday, August 18th, Scott Blumberg sold 990 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total transaction of $24,750.00.

CeriBell Price Performance

NASDAQ CBLL opened at $25.00 on Friday. The company has a market cap of $959.50 million, a PE ratio of -14.20 and a beta of 0.95. The firm’s 50 day moving average price is $21.51 and its 200-day moving average price is $19.79. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $25.63.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The firm had revenue of $28.10 million for the quarter, compared to the consensus estimate of $27.28 million. Sell-side analysts forecast that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

Institutional Investors Weigh In On CeriBell

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CBLL. TimesSquare Capital Management LLC purchased a new position in CeriBell during the second quarter worth about $15,182,000. Bank of New York Mellon Corp acquired a new stake in CeriBell in the 2nd quarter valued at approximately $17,437,000. Royce & Associates LP purchased a new stake in CeriBell in the fourth quarter valued at approximately $11,695,000. BlackRock Inc. acquired a new stake in shares of CeriBell in the second quarter valued at $37,657,000. Finally, Deutsche Bank AG purchased a new stake in shares of CeriBell in the 2nd quarter valued at $1,742,000.

Analyst Ratings Changes

CBLL has been the topic of a number of analyst reports. Barclays upgraded CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Raymond James Financial reiterated a “strong-buy” rating and set a $29.00 target price on shares of CeriBell in a research report on Thursday, September 3rd. BTIG Research reissued a “buy” rating and issued a $30.00 price target on shares of CeriBell in a report on Friday, September 11th. Finally, Canaccord Genuity Group increased their price objective on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $24.40.

CeriBell Company Profile

Ceribell, Inc (NASDAQ: CBLL) is a medical technology company focused on improving the detection and management of seizures and other neurological conditions in hospital settings. Its products are designed to make electroencephalography (EEG) more accessible at the point of care, particularly in emergency departments, intensive care units and other settings where conventional EEG testing may be delayed or difficult to obtain.

The company’s primary offering is the Ceribell Rapid Response EEG system, which combines a portable EEG recorder, a simplified electrode headband and software for acquiring and reviewing brain-wave data.